ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SPPI Spectrum Pharmaceuticals Inc

1.03
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Spectrum Pharmaceuticals Inc NASDAQ:SPPI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.03 1.14 0.9785 0 01:00:00

Statement of Changes in Beneficial Ownership (4)

23/02/2021 10:01pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Turgeon Joseph W.
2. Issuer Name and Ticker or Trading Symbol

SPECTRUM PHARMACEUTICALS INC [ SPPI ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO & President
(Last)          (First)          (Middle)

11500 S. EASTERN AVENUE, SUITE 240
3. Date of Earliest Transaction (MM/DD/YYYY)

2/18/2021
(Street)

HENDERSON, NV 89052
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value 2/18/2021  A  278090 (1)A$0.00 648119 D  
Common Stock, $0.001 par value 2/19/2021  S(2)  7257 D$3.637 640862 D  
Common Stock, $0.001 par value 2/22/2021  S(2)  7500 D$3.73 633362 D  
Common Stock, $0.001 par value         1538 I By 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $3.56 2/18/2021  A   337079     (3)2/18/2031 Common Stock 337079 $0.00 337079 D  
Stock Appreciation Right $3.56 2/18/2021  A   792135     (4)2/18/2031 Common Stock 792135 $0.00 792135 D  

Explanation of Responses:
(1) One third of the aggregate amount of restricted shares shall vest on each of February 18, 2022, 2023 and 2024, respectively.
(2) All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
(3) One third of the aggregate amount of option shares shall vest on each of February 18, 2022, 2023 and 2024, respectively.
(4) One third of the aggregate amount of stock appreciation rights shall vest on each of February 18, 2022, 2023 and 2024, respectively.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Turgeon Joseph W.
11500 S. EASTERN AVENUE
SUITE 240
HENDERSON, NV 89052
X
CEO & President

Signatures
/s/ Kurt A. Gustafson, attorney-in-fact for Joseph W. Turgeon2/23/2021
**Signature of Reporting PersonDate

1 Year Spectrum Pharmaceuticals Chart

1 Year Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock